Fundraising Fox

EnPlusOne Biosciences

Watertown, US · Founded 2022 · Delaware corporation · 3 known investors

En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.

BiotechDeep Tech

Founders & leadership

EnPlusOne Biosciences was founded in 2022 by Daniel Ahlstedt and Jonathan Rittichier.

DA
Daniel AhlstedtCo-founder
JRJonathan Rittichier
Jonathan RittichierinCo-founder · Chief Scientific OfficerFounder at Enplusonebio

Board

PMPaxton Major
Paxton MajorinBoard DirectorManaging Director at Northpond Ventures
ALAndrew Lee
Andrew Leein𝕏Board directorManaging Director at Northpond Ventures
SK
Steven KasokBoard director

Investors · 3

Breakout VenturesSan Francisco · $500K – $6M
Coatue ManagementNew York · $1M – $20M
Northpond Venturesreported · 2 sourcesBethesda · $100K – $5Mvia Paxton Major · board

Reported raises · per SEC filings

Form D private placements

$21.8M disclosed across 1 round · 2022

▶$21.8MraisedDec 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paxton MajorDirector
  • Andrew LeeDirector
  • Steven KasokDirector
  • Daniel AhlstedtExecutive Officer, Director
Offering amount
$23.1M
Amount sold
$21.8M
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

EnPlusOne Biosciences Highlights Significant Advancements to its ezRNA™ Enzymatic RNA Synthesis Platform and Introduces Novel Modifications for Next-Generation RNA Therapeuticsbusinesswire.com · May 2026EnPlusOne Biosciences Appoints Clare Murray, Ph.D. as CEObusinesswire.com · Apr 2025EnPlusOne Biosciences Secures $10M to Enhance RNA Synthesis Platform | Venture Capitalventurecapital.com · Feb 2025EnPlusOne Biosciences Raises $10M in Financingfinsmes.com · Feb 2025EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strandbusinesswire.com · Jul 2024EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing - EnPlusOne Bioenplusonebio.com · Sep 2022

Frequently asked questions

What does EnPlusOne Biosciences do?
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.
Who founded EnPlusOne Biosciences?
EnPlusOne Biosciences was founded by Daniel Ahlstedt, Jonathan Rittichier in 2022.
Who are EnPlusOne Biosciences's investors?
EnPlusOne Biosciences's investors include Breakout Ventures, Coatue Management, Northpond Ventures.
How much funding has EnPlusOne Biosciences raised?
EnPlusOne Biosciences has disclosed $21.8M raised across 1 round.
Where is EnPlusOne Biosciences headquartered?
EnPlusOne Biosciences is headquartered in Watertown, US.